Skip to main content

Day: September 23, 2020

Brasil Aprova Estudo da RedHill Biopharma Fase 2/3 de COVID-19 com Opaganib

O estudo global de Fase 2/3 sendo realizado com opaganib administrado por via oral em pacientes com COVID-19 grave foi aprovado na Itália, Reino Unido, Rússia, Israel, México e Brasil;16 locais clínicos iniciados globalmente até o momento—Paralelamente, o estudo de Fase 2 com opaganib nos EUA, com 8 locais clínicos ativos, já recebeu aproximadamente 75% de inscrições que devem ser encerradas nas próximas semanas—O opaganib inibiu completamente a replicação viral do SARS-CoV-2 em um modelo de células pulmonares humanas in vitro, comparado favoravelmente com remdesivir, o controle positivo no estudo—O opaganib demonstrou dupla atividade anti-inflamatória e antiviral e visa um componente da célula hospedeira, não afetado por mutação viral, minimizando assim a probabilidade de resistência—Pedidos de autorização de...

Continue reading

Automotive Finance Market 2020 Global Industry Size, Revenue Growth Development, Business Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2026

Pune, Sept. 23, 2020 (GLOBE NEWSWIRE) — The Global “Automotive Finance Market” is likely to grow in the coming years with impetus from strategic collaborations among companies from across the world. According to a report published by Fortune Business Insights, titled “Automotive Finance Market Size, Share and Global Trend by Loan Provider (OEMs, Banks, Financing institutions), Service Type (New vehicles, Used vehicles), Industry Verticals (Residential Use, Commercial Use, Government Use), and Geography Forecast till 2025,” the market is likely to expand in the coming years, driven by increasing demand for electric cars and adoption of e-commerce business platforms.Request A Sample Copy of the Market Research Report https://www.fortunebusinessinsights.com/enquiry/sample/automotive-finance-market-100122Nissan Automotive’s...

Continue reading

Intensive Care Unit Equipment Market to Exhibit a CAGR of 4.8% and Reach USD 9.03 Billion by 2027; Inflated Demand for Ventilators During Coronavirus Pandemic to Exhibit Positive Sales Projections, states Fortune Business Insights™

Pune, Sept. 23, 2020 (GLOBE NEWSWIRE) — The global intensive care unit equipment market size is predicted to reach USD 9.03 billion by 2027, exhibiting a CAGR of 4.8% during the forecast period.The emergence of novel viruses such as coronavirus will spur demand for life support, patient monitoring, and emergency resuscitation devices, which in turn, will boost the market growth during the forecast period, states Fortune Business Insights in a report, titled “Intensive Care Unit Equipment Market Size, Share and Covid-19 Impact Analysis, By Product (Beds, Ventilators, Pulse Oximeters, Dialysis Equipment, and Others), By Patient (Adult and Pediatric), By Application (Neurology, Cardiology, Respiratory, Renal, Oncology, Trauma, and Others), By End-User (Hospitals, Specialty Clinics, and Others and Regional Forecast, 2020-2027” the market...

Continue reading

Chronic Wound Care Market to Increase at a CAGR of 6.2% and Reach USD 16.36 Billion by 2027; Presence of Several Large Scale Healthcare Companies will Bode well for Market Growth, says Fortune Business Insights™

Pune, Sept. 23, 2020 (GLOBE NEWSWIRE) — Global chronic wound care market size is projected to reach USD 16.36 billion by the end of 2027. The increasing investment in the technological integration will open up a huge potential for the growth of the overall market. The market was worth USD 10.12 billion in 2019 and will exhibit a CAGR of 6.2% during the forecast period, 2020-2027.Chronic wounds are diseases that haven’t been successfully treated during the process of treatment of repair. The costs associated with chronic wounds are much higher than normal disease treatment. According to data published by the US National Library of Medicine, in 2018, around 5.7 million people in the United States suffered from chronic wound diseases. The high prevalence of the disease will create several growth opportunities for the companies operating...

Continue reading

Immune Health Supplements Market Exhibit 7.4% CAGR and Reach USD 29.40 Billion 2027; Rapid Changes in Lifestyles to Bolster Growth, says Fortune Business Insights™

Pune, Sept. 23, 2020 (GLOBE NEWSWIRE) — The global immune health supplements market is likely to grow astonishingly backed by the increasing popularity of non-GMO and organic ingredients amongst the masses. The trend is further resulting in the rising purchase of organic immunity health supplements worldwide. The report further states that the immune health supplements market size was USD 16.32 billion in 2019 and is projected to reach USD 29.40 billion by 2027, exhibiting a CAGR of 7.4% during the forecast period.This Report Answers the Following Questions:Which are the market drivers, hindrances, and dynamics?Will the companies adopt new strategies to compete in the market?Which segment is expected to dominate the market in terms of share?How will COVID-19 help in generating more sales of immune health supplements?Request a Sample...

Continue reading

Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD

LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of its ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) Phase 3 trials to evaluate the efficacy and safety of nebulized ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease (“COPD”).David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, said: “We are excited to start our pivotal ENHANCE Phase 3 studies. If successful, the data will support the submission of a New Drug Application in the U.S. for nebulized ensifentrine for the maintenance treatment of COPD. This is an important milestone for Verona Pharma and we look forward to addressing the urgent...

Continue reading

Landsvirkjun successfully issues Green Bonds in the US Private Placement market

Among the first companies globally to adopt a new approach to finance green assetsLandsvirkjun has today signed an agreement with US and UK institutional investors to issue USD 150 million senior unsecured notes in the US Private Placement (“USPP”) market in Green Bond format. The notes have been issued under the company’s updated Green Finance Framework (“GFF”) with proceeds to be used to finance and refinance green assets on the company’s balance sheet. Landsvirkjun is among the first companies globally to apply this new balance sheet approach in its GFF. The notes are issued without a state guarantee of collection.The offering was very well received, with the order book totalling USD 545 million, representing over 5x oversubscription from the launch size of USD 100 million. The notes have a 9-year maturity and carry a fixed interest...

Continue reading

Landsvirkjun gefur út græn skuldabréf á Bandaríkjamarkaði

Á meðal fyrstu fyrirtækja í heiminum til að beita nýrri nálgun við fjármögnun grænna eignaLandsvirkjun hefur skrifað undir samning við bandaríska og breska fagfjárfesta um útgáfu grænna skuldabréfa. Um var að ræða lokað skuldabréfaútboð á Bandaríkjamarkaði (e. US private placement), að fjárhæð samtals 150 milljónir Bandaríkjadala, jafnvirði um 21 milljarðs íslenskra króna. Bréfin eru gefin út undir uppfærðum grænum fjármögnunarramma Landsvirkjunar („Green Finance Framework“). Fjármunirnir verða nýttir til að fjármagna og endurfjármagna grænar eignir á efnahagsreikningi fyrirtækisins. Það er ný nálgun í skilgreiningu á ráðstöfun fjármuna samkvæmt græna fjármögnunarrammanum og er Landsvirkjun á meðal fyrstu fyrirtækja á heimsvísu sem beita þessari nýju nálgun. Bréfin eru gefin út án ríkisábyrgðar.Upphaflega var stefnt að skuldabréfaútgáfu...

Continue reading

INGENICO GROUP: Ingenico Group receives the EcoVadis Platinum medal for its CSR performance and joins the top 1 percent of assessed companies

Ingenico Group receives the EcoVadis Platinum medal for its CSR performance and joins the top 1 percent of assessed companiesIngenico Group (Euronext: FR0000125346 – ING), the global leader in seamless payments is proud to receive the Platinum EcoVadis Medal, the highest distinction awarded by the independent platform that assesses companies’ social and environmental performance. This year, with a 4-point improvement on its previous year, Ingenico reaches the global score of 74/100, placing the Group among the top 1 percent of companies assessed by EcoVadis.This progression1 confirms Ingenico’s long term commitment to promoting Corporate Social Responsibility (CSR) within the Group, relying on its dedicated “SHARE2” programme. This 5-year plan follows on from the measures already initiated by the Group in 2015 and is based around...

Continue reading

INGENICO GROUP : Ingenico Group reçoit la médaille Platine d’EcoVadis pour sa performance RSE et rejoint le top 1 % des entreprises évaluées

Ingenico Group reçoit la médaille Platine d’EcoVadis pour sa performance RSE et rejoint le top 1 % des entreprises évaluéesIngenico Group (Euronext: FR0000125346 – ING), leader mondial des solutions de paiement intégrées, est fier d’obtenir la médaille Platine EcoVadis, la plus haute distinction décernée par la plate-forme indépendante d’évaluation des performances sociale et environnementale des entreprises. Cette année, Ingenico améliore de 4 points sa note avec un score global de 74/100 et rejoint le top 1 % des entreprises évaluées par EcoVadis.  Cette nouvelle progression1 vient confirmer l’engagement d’Ingenico depuis plusieurs années en matière de Responsabilité Sociétale de l’Entreprise (RSE), qui s’appuie sur son programme dédié « SHARE2 ». Ce plan à cinq ans s’inscrit dans le prolongement des actions initiées depuis...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.